Molecular determinants of pyrantel selectivity in nicotinic receptors

被引:19
作者
Bartos, Mariana [1 ]
Rayes, Diego [1 ]
Bouzat, Cecilia [1 ]
机构
[1] Univ Nacl Sur, Inst Invest Biomed, Consejo Nacl Invest Cient & Tecn, RA-8000 Bahia Blanca, Buenos Aires, Argentina
关键词
D O I
10.1124/mol.106.026336
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nicotinic receptors (acetylcholine receptors, AChRs) play key roles in synaptic transmission throughout the nervous system. AChRs mediate neuromuscular transmission in nematodes, and they are targets for antiparasitic drugs. The anthelmintic agents levamisole and pyrantel, which are potent agonists of nematode muscle AChRs, are partial agonists of mammalian muscle AChRs. To further explore the structural basis of the differential activation of AChR subtypes by anthelmintics, we studied the activation of alpha 7 AChRs using the high-conductance form of the alpha 7-5-hydroxytryptamine-3A receptor, which is a good model for pharmacological studies involving the extracellular region of alpha 7. Macroscopic and single-channel current recordings show that levamisole is a weak agonist of alpha 7. It is interesting that pyrantel is a more potent agonist of alpha 7 than acetylcholine (ACh). To identify determinants of this differential activation, we replaced residues of the complementary face of the binding site by the homologous residues in the muscle epsilon subunit and evaluated changes in activation. The mutation Q57G does not affect the activation by either ACh or levamisole. However, it increases EC50 values and decreases the maximal response to pyrantel. Kinetic analysis shows that gating of the mutant channel activated by pyrantel is profoundly impaired. The decreased sensitivity of alpha 7-Q57G to pyrantel agrees with its weak action at muscle AChRs, indicating that when glycine occupies position 57, as in the mammalian muscle AChR, pyrantel behaves as a partial agonist. Thus, position 57 located at the complementary face of the binding site plays a key role in the selective activation of AChRs by pyrantel.
引用
收藏
页码:1307 / 1318
页数:12
相关论文
共 36 条
[1]   Activation of heteroliganded mouse muscle nicotinic receptors [J].
Akk, G ;
Milescu, LS ;
Heckmann, M .
JOURNAL OF PHYSIOLOGY-LONDON, 2005, 564 (02) :359-376
[2]   Activation of GABAA receptors containing the α4 subunit by GABA and pentobarbital [J].
Akk, G ;
Bracamontes, J ;
Steinbach, JH .
JOURNAL OF PHYSIOLOGY-LONDON, 2004, 556 (02) :387-399
[3]   RESISTANCE TO LEVAMISOLE AND CROSS-RESISTANCE BETWEEN PYRANTEL AND LEVAMISOLE IN OESOPHAGOSTOMUM-QUADRISPINULATUM AND OESOPHAGOSTOMUM-DENTATUM OF PIGS [J].
BJORN, H ;
ROEPSTORFF, A ;
WALLER, PJ ;
NANSEN, P .
VETERINARY PARASITOLOGY, 1990, 37 (01) :21-30
[4]   Nicotinic receptor fourth transmembrane domain - Hydrogen bonding by conserved threonine contributes to channel gating kinetics [J].
Bouzat, C ;
Barrantes, F ;
Sine, S .
JOURNAL OF GENERAL PHYSIOLOGY, 2000, 115 (05) :663-671
[5]   Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel [J].
Bouzat, C ;
Gumilar, F ;
Spitzmaul, G ;
Wang, HL ;
Rayes, D ;
Hansen, SB ;
Taylor, P ;
Sine, SM .
NATURE, 2004, 430 (7002) :896-900
[6]   Subunit-selective contribution to channel Gating of the M4 domain of the nicotinic receptor [J].
Bouzat, C ;
Gumilar, F ;
Esandi, MD ;
Sine, SM .
BIOPHYSICAL JOURNAL, 2002, 82 (04) :1920-1929
[7]   STRUCTURAL BASIS OF THE DIFFERENT GATING KINETICS OF FETAL AND ADULT ACETYLCHOLINE-RECEPTORS [J].
BOUZAT, C ;
BREN, N ;
SINE, SM .
NEURON, 1994, 13 (06) :1395-1402
[8]   Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors [J].
Brejc, K ;
van Dijk, WJ ;
Klaassen, RV ;
Schuurmans, M ;
van der Oost, J ;
Smit, AB ;
Sixma, TK .
NATURE, 2001, 411 (6835) :269-276
[9]   Structure of the agonist-binding sites of the Torpedo nicotinic acetylcholine receptor:: Affinity-labeling and mutational analyses identify γTyr-111/δArg-113 as antagonist affinity determinants [J].
Chiara, DC ;
Xie, Y ;
Cohen, JB .
BIOCHEMISTRY, 1999, 38 (20) :6689-6698
[10]  
Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924